checkAd
    Startseite > Aktien > PureTech Health > Nachrichten
    PureTech Health Aktie
    28,75
     
    USD
    +4,93 %
    +1,35 USD
    Letzter Kurs 16.05.24 Nasdaq
    26,26
     
    USD
    100 STK
    Geldkurs 16.05.24
    29,52
     
    USD
    100 STK
    Briefkurs 16.05.24
    ISIN: US7462371060 · WKN: A3DB9P · SYM: PRTC · Großbritannien

    Neueste Nachrichten

    PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
    09.05.24 · Business Wire (engl.) · PureTech Health
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
    07.05.24 · Business Wire (engl.) · PureTech Health
    PureTech Announces Annual Results for Year Ended December 31, 2023
    25.04.24 · Business Wire (engl.) · PureTech Health
    PureTech Health: Notice of Results
    18.04.24 · Business Wire (engl.) · PureTech Health
    PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
    16.04.24 · Business Wire (engl.) · PureTech Health
    PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
    11.04.24 · Business Wire (engl.) · PureTech Health
    PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
    09.04.24 · Business Wire (engl.) · PureTech Health
    PureTech Proposes $100 Million Capital Return
    19.03.24 · Business Wire (engl.) · PureTech Health
    Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
    18.03.24 · Business Wire (engl.) · PureTech Health
    PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
    13.03.24 · Business Wire (engl.) · PureTech Health
    PureTech to Present at Two Upcoming Investor Conferences
    27.02.24 · Business Wire (engl.) · PureTech Health
    PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx for Pediatric ADHD Patients in Japan
    27.02.24 · Business Wire (engl.) · PureTech Health